Arcutis Biotherapeutics Inc (NASDAQ:ARQT) traded at $15.64 at close of the session on Monday, March 31 and made a downward move of -0.57% on its previous day’s price.
Looking at the stock we see that its previous close was $15.73 and the beta (5Y monthly) reads 1.488 with the day’s price range being $14.76 – $16.11. In terms of its 52-week price range, ARQT has a high of $17.75 and a low of $6.99. The company’s stock has gained about 14.24% over that past 30 days.
Arcutis Biotherapeutics Inc has a market cap of $1.86 billion and is expected to release its quarterly earnings report on 2025-Feb-24.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at 64.1M, with a low of 57.8M and a high of 70M. The median projection represents growth squeezing down to 29.32% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 301.79M, or 53.55% up from figures reported last year.
On the other hand, looking at the outlook for the ARQT stock, short term indicators assign the stock an average of 75% Buy, while medium term indicators assign it an average of 100% Buy.
Based on estimates by 3 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Arcutis Biotherapeutics Inc (ARQT) stock as a Hold, while 2 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 1 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is -0.02% off its SMA20 and 11.40% from its 50-day simple moving average. The RSI (14) is pointing at 53.11 while the volatility over the past week is 6.33% and jumps to 7.93% over the past one month. The beta value is 1.66, while the average true range (ATR) is currently pointing at 1.09. The average price target for the stock over the next 12 months is $19, with the estimates having a low of $19 and a high of $19. These price ends are -21.48% and -21.48% off the current price level respectively, although investors could be excited at the prospect of a -21.48% if the ARQT share price touches on the median price of $19.
Coming back to Arcutis Biotherapeutics Inc (NASDAQ:ARQT), we note that the average 3-month trading volume was 2.31 million, while that of the preceding 10-day period stands at 2.42 million. Current shares outstanding are 117.85 million.
The insiders hold 12.01% of the company’s shares while institutions hold 102.23%. The data shows that short shares as of 2025-03-14, stood at 15.11 million at a short ratio of 6.95. This represents a 1570.00 short interest in shares outstanding on 2025-03-14. Shares short fall in March from the previous month at 17.64 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 12.28% up in year-to-date price movement.
